Regeneron's antibody cocktail improves COVID-19 patients

By The Science Advisory Board staff writers

September 30, 2020 -- An investigational antibody cocktail by Regeneron Pharmaceuticals reduced the viral loads and improved the systems of nonhospitalized COVID-19 patients, according to data from its phase I/II/III trial.

REGN-COV2, a combination of two monoclonal antibodies, also had a positive effect in reducing medical visits, according to the ongoing, randomized double-blind trial that aims to measure the benefit of adding REGN-COV2 to the usual standard of care. Of the first 275 patients enrolled, approximately 45% were seropositive and 41% were seronegative. REGN-COV2 reduced viral load through day seven in seronegative patients.

The trial is included in a larger research program that is studying the cocktail for treating hospitalized patients and for preventing infections in those who have been exposed to COVID-19 patients.

Regeneron begins phase III trial of COVID-19 treatment in U.K.
Regeneron Pharmaceuticals and the University of Oxford have commenced a phase III clinical trial of potential treatments for COVID-19.
Regeneron, Roche increase supply of COVID-19 antibody cocktail
Regeneron Pharmaceuticals and Roche are joining forces to develop, manufacture, and distribute Regn-COV2, Regeneron's investigational antiviral antibody...
BARDA awards supply contract to Regeneron for COVID-19 cocktail
Regeneron Pharmaceuticals was awarded a $450 million contract to manufacture and supply its REGN-COV2 antibody cocktail that is currently in phase...
Regeneron begins COVID-19 antibody treatment phase III trial
Regeneron Pharmaceuticals has begun adaptive late-stage phase III clinical trials evaluating its antibody cocktail, REGN-COV2, for the treatment and prevention...
Regeneron begins clinical trials for COVID-19 antibody treatment
Regeneron Pharmaceuticals has started its first clinical trial investigating an antibody treatment for COVID-19.

Copyright © 2020

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter